Skip to main content
main-content

15.10.2015 | Original Contributions | Ausgabe 5/2016

Obesity Surgery 5/2016

Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Zeitschrift:
Obesity Surgery > Ausgabe 5/2016
Autoren:
Scott A. Shikora, James Toouli, Miguel F Herrera, Bård Kulseng, Roy Brancatisano, Lilian Kow, Juan P. Pantoja, Gjermund Johnsen, Anthony Brancatisano, Katherine S. Tweden, Mark B. Knudson, Charles J. Billingto
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11695-015-1914-1) contains supplementary material, which is available to authorized users.
An erratum to this article can be found at http://​dx.​doi.​org/​10.​1007/​s11695-015-1951-9.

Abstract

Background

One-year results of the VBLOC DM2 study found that intermittent vagal blocking (VBLOC therapy) was safe among subjects with obesity and type 2 diabetes mellitus (T2DM) and led to significant weight loss and improvements in glycemic parameters and cardiovascular risk factors. Longer-term data are needed to determine whether the results are sustained.

Methods

VBLOC DM2 is a prospective, observational study of 28 subjects with T2DM and body mass index (BMI) between 30 and 40 kg/m2 to assess mid-term safety and weight loss and improvements in glycemic parameters, and other cardiovascular risk factors with VBLOC therapy. Continuous outcome variables are reported using mixed models.

Results

At 24 months, the mean percentage of excess weight loss was 22 % (95 % CI, 15 to 28, p < 0.0001) or 7.0 % total body weight loss (95 % CI, 5.0 to 9.0, p < 0.0001). Hemoglobin A1c decreased by 0.6 percentage points (95 % CI, 0.2 to 1.0, p = 0.0026) on average from 7.8 % at baseline. Fasting plasma glucose declined by 15 mg/dL (95 % CI, 0 to 29, p = 0.0564) on average from 151 mg/dL at baseline. Among subjects who were hypertensive at baseline, systolic blood pressure declined 10 mmHg (95 % CI, 2 to 19, p = 0.02), diastolic blood pressure declined by 6 mmHg (95 % CI, 0 to 12, p = 0.0423), and mean arterial pressure declined 7 mmHg (95 % CI, 2 to 13, p = 0.014). Waist circumference was significantly reduced by 7 cm (95 % CI, 4 to 10, p < 0.0001) from a baseline of 120 cm. The most common adverse events were mild or moderate heartburn, implant site pain, and constipation.

Conclusions

Improvements in obesity and glycemic control were largely sustained after 2 years of treatment with VBLOC therapy with a well-tolerated risk profile.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
ESM 1 (DOC 34 kb)
11695_2015_1914_MOESM1_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 5/2016

Obesity Surgery 5/2016 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise